Can we preoperatively risk stratify ovarian masses for malignancy?

被引:127
作者
Oltmann, Sarah C. [1 ]
Garcia, Nilda [1 ]
Barber, Robert [2 ]
Huang, Rong [2 ]
Hicks, Barry [1 ]
Fischer, Anne [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75235 USA
[2] Childrens Med Ctr, Dallas, TX 75235 USA
关键词
Ovarian mass; Ovarian malignancy; Pediatric surgery; Gynecology; GERM-CELL TUMORS; CHILDREN; ADOLESCENTS; SURGERY;
D O I
10.1016/j.jpedsurg.2009.10.022
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose: Given a 10% malignancy rate in pediatric ovarian masses, what preoperative factors are helpful in distinguishing those at higher risk to risk stratify accordingly? Methods: After institutional review board approval (IRB# 022008-095), a 15-year retrospective review of operative ovarian cases was performed. Results: A total of 424 patients were identified, with a mean age 12.5 years (range, 1 day to 19 years), without an age disparity between benign (12.54 years, 89%) and malignant (11.8 years, 11%) cases. The 1- to 8-year age group had the highest percentage of malignancies (22%; odds ratio [OR], 3.02; 95% confidence interval [CI], 1.33-6.86). A chief complaint of mass or precocious puberty versus one of pain had an OR for malignancy of 4.84 and 5.67, respectively (95% CI, 2.48-9.45 and 1.60-20.30). Imaging of benign neoplasms had a mean size of 8 cm (range, 0.9-36 cm) compared with malignancies at 17.3 cm (6.2-50 cm, P < .001). An ovarian mass size of 8 cm or longer on preoperative imaging had an OR of 19.0 for malignancy (95% CI, 4.42-81.69). Ultrasound or computed tomographic findings of a solid mass, although infrequent, were most commonly associated with malignancy (33%-60%), compared with reads of heterogeneous (15%-21%) or cystic (4%-5%) lesions. The malignancies (n = 46) included germ cell (50%, n = 23), stromal (28%, n = 13), epithelial (17%, n = 8), and other (4%, n = 2). Tumor markers obtained in 71% of malignancies were elevated in only 54%, whereas 6.5% of those sent in benign cases were similarly elevated. Elevated beta-human chorionic gonadotropin (beta-HCG), alpha fetoprotein (alpha FP), and cancer antigen 125 (CA-125) were significantly associated with malignancy (P < .02) and an elevated carcinoembryonic antigen (CEA) was not (P = .1880). Conclusion: This reported series of pediatric ovarian masses demonstrates that preoperative indicators that best predict an ovarian malignancy are a complaint of a mass or precocious puberty, a mass exceeding 8 cm or a mass with solid imaging characteristics. Those patients aged 1 to 8 years have the greatest incidence of malignancy. Tumor markers, positive or negative, were not conclusive in all cases but useful for postoperative surveillance. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 50 条
[31]   Comparison of Simple Ultrasound Rules by International Ovarian Tumor Analysis (IOTA) with RMI-1 and RMI-4 (Risk of Malignancy Index) in Preoperative Differentiation of Benign and Malignant Adnexal Masses [J].
Shalinee Dewangan ;
Sonal Gupta ;
Indu Chawla .
The Journal of Obstetrics and Gynecology of India, 2024, 74 :158-164
[32]   Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China [J].
He, Ping ;
Wang, Jing-jing ;
Duan, Wei ;
Song, Chao ;
Yang, Yu ;
Wu, Qing-qing .
JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
[33]   Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods [J].
Meys, E. M. J. ;
Jeelof, L. S. ;
Achten, N. M. J. ;
Slangen, B. F. M. ;
Lambrechts, S. ;
Kruitwagen, R. F. P. M. ;
Van Gorp, T. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2017, 49 (06) :784-792
[34]   Commentary: Shallwewait for two days more? Can we take this risk? [J].
D'Alessandro, Stefano ;
Guarracino, Fabio ;
Nicolini, Francesco ;
Formica, Francesco .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 163 (03) :1056-1057
[35]   Should Cut-Off Values of the Risk of Malignancy Index be Changed for Evaluation of Adnexal Masses in Asian and Pacific Populations? [J].
Yavuzcan, Ali ;
Caglar, Mete ;
Ozgu, Emre ;
Ustun, Yusuf ;
Dilbaz, Serdar ;
Ozdemir, Ismail ;
Yildiz, Elif ;
Gungor, Tayfun ;
Kumru, Selahattin .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (09) :5455-5459
[36]   Use of a standardized reporting template: can we improve report quality in pancreatic and peri-ampullary malignancy? [J].
Hodnett, Robert ;
MacCormick, Andrew ;
Ibrahim, Rashid ;
Miles, Gemma ;
Puckett, Mark ;
Aroori, Somaiah .
ANZ JOURNAL OF SURGERY, 2022, 92 (1-2) :109-113
[37]   Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis [J].
Bergamini, Alice ;
Sarwar, Naveed ;
Ferrandina, Gabriella ;
Scarfone, Giovanna ;
Short, Dee ;
Aguiar, Xianne ;
Camnasio, Cristina ;
Kaur, Baljeet ;
Savage, Philip M. ;
Cormio, Gennaro ;
Lim, Adrian ;
Pignata, Sandro ;
Mangili, Giorgia ;
Seckl, Michael J. .
EUROPEAN JOURNAL OF CANCER, 2020, 137 :136-143
[38]   CAN WE DO BETTER?: The Assessment of Risk of Recidivism by Adult Sex Offenders [J].
Parent, Genevieve ;
Guay, Jean-Pierre ;
Knight, Raymond A. .
CRIMINAL JUSTICE AND BEHAVIOR, 2012, 39 (12) :1647-1667
[39]   External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk Groups [J].
Timmerman, Stefan ;
Valentin, Lil ;
Ceusters, Jolien ;
Testa, Antonia C. ;
Landolfo, Chiara ;
Sladkevicius, Povilas ;
Van Holsbeke, Caroline ;
Domali, Ekaterini ;
Fruscio, Robert ;
Epstein, Elisabeth ;
Franchi, Dorella ;
Kudla, Marek J. ;
Chiappa, Valentina ;
Alcazar, Juan L. ;
Leone, Francesco P. G. ;
Buonomo, Francesca ;
Coccia, Maria Elisabetta ;
Guerriero, Stefano ;
Deo, Nandita ;
Jokubkiene, Ligita ;
Kaijser, Jeroen ;
Scambia, Giovanni ;
Andreotti, Rochelle ;
Timmerman, Dirk ;
Bourne, Tom ;
Van Calster, Ben ;
Froyman, Wouter .
JAMA ONCOLOGY, 2023, 9 (02) :225-233
[40]   Re: 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis' [J].
Lockley, Michelle ;
Stoneham, Sara ;
Shamash, Jonathan ;
Pashankar, Farzana ;
Frazier, Lindsay .
EUROPEAN JOURNAL OF CANCER, 2021, 152 :255-256